Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil

Texto completo
Autor(es):
Toledo, Rodrigo A. [1] ; Sekiya, Tomoko [1] ; Longuini, Viviane C. [1] ; Coutinho, Flavia L. [1] ; Lourenco, Jr., Delmar M. [1] ; Toledo, Sergio P. A. [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Endocrine Genet Unit LIM 25, Endocrinol Div, Sao Paulo - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo de Revisão
Fonte: Clinics; v. 67, n. 1, p. 3-6, 2012.
Citações Web of Science: 6
Resumo

The finished version of the human genome sequence was completed in 2003, and this event initiated a revolution in medical practice, which is usually referred to as the age of genomic or personalized medicine. Genomic medicine aims to be predictive, personalized, preventive, and also participative (4Ps). It offers a new approach to several pathological conditions, although its impact so far has been more evident in mendelian diseases. This article briefly reviews the potential advantages of this approach, and also some issues that may arise in the attempt to apply the accumulated knowledge from genomic medicine to clinical practice in emerging countries. The advantages of applying genomic medicine into clinical practice are obvious, enabling prediction, prevention, and early diagnosis and treatment of several genetic disorders. However, there are also some issues, such as those related to: (a) the need for approval of a law equivalent to the Genetic Information Nondiscrimination Act, which was approved in 2008 in the USA; (b) the need for private and public funding for genetics and genomics; (c) the need for development of innovative healthcare systems that may substantially cut costs (e.g. costs of periodic medical follow-up); (d) the need for new graduate and postgraduate curricula in which genomic medicine is emphasized; and (e) the need to adequately inform the population and possible consumers of genetic testing, with reference to the basic aspects of genomic medicine. (AU)

Processo FAPESP: 09/15386-6 - Análise dos genes CDKN1A, CDKN1B, CDKN2B e CDKN2C, nas Neoplasias Endócrinas Múltiplas tipo 1 e 2
Beneficiário:Rodrigo de Almeida Toledo
Linha de fomento: Bolsas no Brasil - Pós-Doutorado